Sopot

• A study to investigate the efficacy and safety of brivekimig in adult participants with ulcerative colitis. Recruiting
  2024-515241-41-00 4 2025-09-10 Ulcerative Colitis
• A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease. Recruiting
  2024-512633-32-00 4 2025-04-07 Crohn's disease
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease
• A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-508158-24-00 4 2024-06-25 Moderately to Severely Active Crohn’s Disease
• Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting
  2022-501119-14-01 4 2024-04-16 Ulcerative Colitis
• A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerabilit … Recruiting
  2023-504835-42-00 4 2024-02-29 Heart Failure (Heart Failure with Reduced Ejection Fraction)
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• A Study to Assess the Effectiveness and Safety of RO7790121 for Induction Therapy in Participants with Moderately to Severely Active Ulcerat … Ended recruitment
  2024-513015-27-00 5 2025-01-09 Moderately to Severely Active Ulcerative Colitis (UC)
• A study looking at how effective and safe AZD7798 is in people with Crohn's disease Ended recruitment
  2023-510487-12-00 4 2024-11-29 Crohn's Disease
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim … Ended recruitment
  2023-506183-13-00 4 2024-03-29 Alzheimer’s Disease
• A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended recruitment
  2022-502442-27-00 5 2024-01-08 Obesity
• A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease. Ended recruitment
  2022-502789-26-01 4 2023-11-03 Fibrostenotic Crohn’s Disease
• A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe … Ended recruitment
  2022-501644-15-01 4 2023-09-28 Mild Cognitive Impairment due to Alzheimer's Disease Alzheimer's Disea
• A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended recruitment
  2024-515027-11-00 4 2023-06-29 Crohn’s disease
• A Phase 2b Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC Ended recruitment
  2022-500953-17-00 4 2023-03-23 Moderately to severely active ulcerative colitis
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended recruitment
  2023-504741-32-00 4 2022-11-30 Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit … Ended recruitment
  2023-504743-13-00 4 2022-11-30 Moderately to Severely Active Ulcerative Colitis
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended recruitment
  2022-502841-91-00 5 2020-08-12 Crohn’s Disease
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2023-504718-31-00 10 2019-10-19 Moderately to Severely Active Ulcerative Colitis
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended recruitment
  2023-506994-36-00 5 2018-10-11 Ulcerative Colitis
• LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended recruitment
  2023-507657-15-00 5 2018-09-13 Ulcerative Colitis

Showing 25–48 of 74 trials